CSCB Virtual Seminar Series

Hyperactive RAS/RAF/MEK/ERK Signaling: A Promising Target For Cancer Therapy.

Date: 7th June 2021 (Monday)
Time: 12noon-1pm (SGT)

Venue: *via* Zoom
https://nus-sg.zoom.us/j/87969099245

Meeting ID: 879 6909 9245
Passcode: 178323

Abstract:
Hyperactive RAS/RAF/MEK/ERK signaling has well-defined role in cancer biology and targeting this signaling pathway by RAF inhibitors has achieved a promising progression in cancer therapy. However, these inhibitors have only a short-term efficacy (6-8 months) on cancers driven by BRAF (V600E) mutation, and there are no targeted therapeutic drugs available for cancers that have RAS mutations or develop resistance to RAF/MEK inhibitors. Dr. Hu's group utilizes molecular biology, biochemistry and animal models to understand molecular mechanisms that govern the regulation of RAS/RAF/MEK/ERK signaling cascade in normal and cancer cells as well as the RAF inhibitor resistance, and hence develop novel approaches for effectively treating cancers with RAS/RAF mutations. He has significantly contributed to our understanding of the activating mechanism of RAF/MEK/ERK kinase cascade (Hu et al., PNAS, 2011, Cell 2013; Yuan et al., Oncogene,Ò018, Sci. Signal., 2018) and the molecular basis of RAF Inhibitor resistance (Yap et al., Sci. Adv., 2021).



Speaker:

Dr. Hu Jiancheng

Principal Investigator, National Cancer Centre Singapore
Assistant Professor, Programme in Cancer & Stem Cell Biology, Duke-NUS Medical School

Dr. Hu completed his Ph.D training at University of Colorado Health Sciences Centre in 2007 and postdoc training at Washington University in Saint Louis in 2014. He moved to Singapore and set up his laboratory at National Cancer Centre Singapore in November 2014. His research interests includes: 1) RAS/RAF/MEK/ERK Signaling, (2) Small Molecule Kinase Inhibitors, and (3) Drug Resistance in Cancer Therapy.

Host:

Kanaga Sabapathy
Professor & Deputy Director
Programme in Cancer & Stem Cell Biology
Duke-NUS Medical School
Singapore

No registration is required.
All are welcome.